Drug industry heavyweights: Research cuts threaten U.S.

03/6/2013 | Forbes

Public funding of agencies that support scientific and biomedical research pays significant dividends and should be restored immediately, write former Genentech chief scientific officer Marc Tessier-Lavigne, Regeneron Pharmaceuticals chairman P. Roy Vagelos and former NIH Director and Sanofi R&D president Elias Zerhouni. Great strides have been made in cardiovascular and HIV/AIDS research thanks to NIH funding, but Alzheimer's disease, diabetes and other chronic diseases threaten to break the nation's bank in the absence of investments in research, they write. Even before sequestration, steadily eroding funds squeezed research and sent many U.S. scientists abroad, harming U.S. competitiveness, they write.

View Full Article in:

Forbes